← Back

Jaguar Animal Health Inc

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments: Animal Health and Human Health. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, and Canalevia-CA1, a prescription drug for chemotherapy-induced diarrhea in dogs. The company is also developing Crofelemer in Phase III trials for prophylaxis of diarrhea in adult cancer patients and in Phase II trials for rare/orphan disease indications, diarrhea-predominant irritable bowel syndrome, and idiopathic/functional diarrhea. Additionally, it is developing Mytesi in Phase III trials for cancer therapy-related diarrhea and Phase II trials for irritable bowel syndrome, as well as NP-300, a second-generation antidiarrheal drug in Phase I trials for moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Country
Price · split & dividend adjusted
News & notes moving JAGX
JAGX

Jaguar Health Sets 1-for-15 Reverse Stock Split for September 17

Jaguar Health, Inc. will effect a 1-for-15 reverse stock split of its issued and outstanding voting common stock on Thursday, September 17, 2026, in order to support the Company's compliance with Nasdaq's listing standards. The Company's common stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol JAGX, with a new CUSIP number of 47010C854. The reverse stock split follows stockholder approval of a proposal submitted at the Company's April 2026 Special Meeting of Stockholders, described in the definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on March 24, 2026. When the split becomes effective, every fifteen shares of common stock immediately prior to the Effective Date will automatically be reclassified into one share, with no change in par value per share, and no fractional shares will be issued, with stockholders entitled to a fractional share receiving a cash payment in lieu thereof. Equiniti Trust Company, LLC is acting as exchange agent and will send instructions to stockholders of record holding stock certificates, while stockholders holding shares in brokerage accounts or street name are not required to take any action.
JAGX
Jaguar Health, Inc.·3dRead more →
JAGX▲

Jaguar Health Launches Neonorm Dog on Amazon

Jaguar Health, Inc. announced that Neonorm Dog, its non-prescription plant-based product for supporting normal stool consistency and GI fluid balance in dogs, is now available on Amazon. This launch extends Jaguar's existing Neonorm franchise, which currently includes Neonorm Foal and Neonorm Calf for pre-weaned foals and calves, into the companion animal market. Jaguar expects Neonorm Dog to be available through other select online and animal health retail channels shortly, including Chewy. The product contains a standardized botanical extract from the sustainably harvested Croton lechleri tree, which acts locally in the gut. Jaguar's Chief Business Officer, Ian Wendt, highlighted the product's role in providing dog owners with a convenient, science-based option for managing episodes of loose stools.
JAGX ▲
ACCESS Newswire·10dRead more →
JAGX▲

Jaguar Health Launches Neonorm Dog for Canine Digestive Support

Jaguar Health, Inc. has initiated the commercial launch of Neonorm Dog, a non-prescription, plant-based product designed to support normal stool consistency and GI fluid balance in dogs, extending its Neonorm franchise beyond foals and calves. The company expects the product to be available soon through Amazon and Chewy, broadening its footprint in the companion animal market. Neonorm Dog contains a standardized botanical extract from the sustainably harvested Croton lechleri tree, which acts locally in the gut. Jaguar's Chief Business Officer Ian Wendt highlighted the product as a science-backed alternative to home remedies, and CEO Lisa Conte emphasized its role in managing common digestive episodes in dogs. The launch targets the large dog-owning populations in the United States and Europe, aiming to reach pet owners, veterinarians, and animal health retailers seeking non-antibiotic options.
JAGX ▲
ACCESS Newswire·23dRead more →
JAGX▲

Jaguar Health targets mid-2027 MVID NDA filing with possible end-2027 U.S. approval

Jaguar Health said it plans to submit a new drug application for crofelemer powder-for-oral-solution in microvillus inclusion disease, or MVID, in late second quarter 2027, with potential U.S. approval by end-2027 if breakthrough therapy designation is granted. CEO Lisa Conte said the company aims to complete enough patients in its treatment-only blinded trial by the fourth quarter of 2026 to file for breakthrough designation, and the clinical package for the NDA is expected to be ready by end-2026. Conte highlighted ESPGHAN data showing weekly parenteral support requirements normalized to body weight were reduced by up to 48% in one MVID patient and up to 40% in two short bowel syndrome with intestinal failure patients. CFO Carol Lizak reported second quarter 2026 prescription product revenue of approximately $1.2 million, primarily from Mytesi sales at cost plus to Future Pak, and a net loss attributable to common shareholders of $12.7 million. The company also recognized a $2 million holdback payment from Future Pak and license fees of $43,000 in the quarter.
JAGX ▲
Seeking Alpha·30dRead more →
JAGX▲

Jaguar Health Reports Positive Market Research for Neonorm Dog Launch

Jaguar Health announced positive findings from exploratory surveys of dog owners and veterinary oncologists supporting the commercial opportunity for Neonorm Dog, a new plant-based product designed to support normal stool consistency and GI fluid balance in dogs. In a survey of 33 veterinary oncologists, nearly 90% viewed the Neonorm Dog concept as clinically relevant and almost 80% indicated they would be likely to recommend it for selected canine oncology patients. A separate survey of 18 dog owners found that 83% found the concept very or extremely appealing and 94% indicated they would definitely or probably purchase the product. Jaguar expects to make Neonorm Dog available through select online and animal health retail channels, including Amazon and Chewy, as part of a planned launch to broaden its commercial footprint in the companion animal market.
JAGX ▲
ACCESS Newswire·52dRead more →
© 2026 MarketDXAsset